论文部分内容阅读
目的:评价卡培他滨与草酸铂联用对晚期大肠癌患者的临床疗效与安全性。方法:选取2014年4月—2015年4月收治的晚期大肠癌患者80例,将其随机分为对照组和治疗组,每组40例;对照组患者均给予口服卡培他滨治疗,治疗组患者在对照组基础上加用草酸铂治疗,比较两组患者治疗后的总有效率及不良反应的发生率。结果:治疗组患者临床治疗后的总有效率为62.50%,明显高于对照组为30.00%(P<0.05);治疗组进展率为10.00%,明显低于对照组为22.50%(P<0.05);治疗组患者用药后恶心呕吐、神经毒性、腹泻、血小板计数下降、胆红素增高等不良反应的发生率明显低于对照组(P<0.05)。结论:采用卡培他滨与草酸铂联用治疗晚期大肠癌患者的疗效优于单用卡培他滨的临床疗效,且不良反应的发生率较低。
Objective: To evaluate the clinical efficacy and safety of capecitabine in combination with oxaliplatin for patients with advanced colorectal cancer. Methods: Eighty patients with advanced colorectal cancer who were admitted from April 2014 to April 2015 were randomly divided into control group and treatment group, 40 cases in each group. Patients in control group were treated with capecitabine orally The patients in the control group were treated with oxaliplatin, and the total effective rate and the incidence of adverse reactions were compared between the two groups after treatment. Results: The total effective rate of the treatment group after treatment was 62.50%, which was significantly higher than that of the control group (30.00%, P <0.05). The progress rate of the treatment group was 10.00%, significantly lower than that of the control group (22.50% ). The incidence of nausea and vomiting, neurotoxicity, diarrhea, decreased platelet count and increased bilirubin in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion: The curative effect of capecitabine combined with oxaliplatin in patients with advanced colorectal cancer is better than capecitabine alone, and the incidence of adverse reactions is lower.